CARLSBAD, Calif.--(

--(

BUSINESS WIRE

商业热线

)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company

)--Argonaut Manufacturing Services（“Argonaut”），一家服务于生物制药和生命科学行业的领先合同开发和制造组织，以及Akoya Biosciences，Inc.（纳斯达克代码：AKYA）（“Akoya”），一家空间生物公司

®

®

, announced today that Argonaut will act as the manufacturing partner for Akoya’s IVD assays currently in development. This agreement builds on years of collaboration between Argonaut and Akoya, reflecting Argonaut’s proven ability to support both emerging and mature diagnostic product lines. Furthermore, this expanded collaboration underscores both companies’ commitment to advancing precision medicine through high-quality diagnostics..

，今天宣布Argonaut将作为目前正在开发的Akoya IVD检测的制造合作伙伴。该协议建立在Argonaut和Akoya多年合作的基础上，反映了Argonaut已证明能够支持新兴和成熟的诊断产品线。此外，这种扩大的合作强调了两家公司通过高质量诊断推进精准医学的承诺。。

'Argonaut and Akoya have built a trusted relationship over the years,' said Wayne Woodard, Founder and CEO of Argonaut. “We’ve successfully supported their Research Use only (RUO) portfolio, and we are thrilled to extend this partnership into the highly regulated companion diagnostic space. Akoya’s innovative solutions in spatial biology are shaping the future of precision medicine, and we are proud to play a role in bringing their vision to life.“.

Argonaut创始人兼首席执行官韦恩·伍德德（WayneWoodard）说，Argonaut和Akoya多年来建立了一种值得信赖的关系。“我们成功地支持了他们的研究用途（RUO）组合，我们很高兴将这种合作关系扩展到高度监管的伴侣诊断领域。Akoya在空间生物学方面的创新解决方案正在塑造精准医学的未来，我们很自豪能在将他们的愿景变为现实方面发挥作用。”。

“Our spatial phenotyping technology and PhenoImager platform are demonstrating robust diagnostic capabilities for patient selection,” commented Brian McKelligon, CEO of Akoya. “Our partnership with Argonaut is centered around delivering high-quality IVD products to our clients, manufactured under strict cGMP and ISO 13485:2016 requirements.

“我们的空间表型分析技术和PhenoImager平台正在展示强大的患者选择诊断能力，”Akoya首席执行官Brian McKelligon评论道。“我们与Argonaut的合作关系以向客户提供高质量的IVD产品为中心，这些产品是根据严格的cGMP和ISO 13485:2016要求制造的。

Argonaut’s deep expertise and reliable systems make them an invaluable partner as we scale to meet the demand of the market.”.

Argonaut深厚的专业知识和可靠的系统使其成为我们满足市场需求的宝贵合作伙伴。”。

“Companion diagnostics are a cornerstone of Argonaut’s commitment to regulated markets, especially in light of evolving FDA requirements,” Wayne Woodard added. “Our agile manufacturing systems, empower organizations like Akoya to reliably and efficiently scale their IVD offerings helping them meet the growing demand for precision medicine solutions.”.

Wayne Woodard补充道：“伴随诊断是Argonaut致力于监管市场的基石，特别是考虑到FDA不断变化的要求。”。“我们的敏捷制造系统使像Akoya这样的组织能够可靠有效地扩展其IVD产品，帮助他们满足对精准医学解决方案日益增长的需求。”。

Akoya Forward-Looking Statements

Akoya前瞻性声明

This press release contains forward-looking statements that are based on Akoya management’s beliefs and assumptions and on information currently available to Akoya management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements concerning expectations about the potential of spatial biology, the demand for precision medicine solutions, the size of the IVD market, the capabilities and potential of Akoya’s products and services, Akoya’s ability to develop, commercialize and meet the demand for its future IVD offerings, and other statements regarding Akoya’s products and services, its partnership with Argonaut, its future performance and its plans and objectives for future operations..

本新闻稿包含基于Akoya管理层的信念和假设以及Akoya管理层目前可获得的信息的前瞻性声明。除历史事实声明外，本版本中包含的所有声明均为前瞻性声明，包括关于空间生物学潜力、精准医学解决方案需求、IVD市场规模、Akoya产品和服务的能力和潜力、Akoya开发、商业化和满足其未来IVD产品需求的能力的声明，以及关于Akoya产品和服务、与Argonaut的合作关系、未来业绩及其未来运营计划和目标的其他声明。。

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

在某些情况下，您可以通过“可能”、“将”、“可能”、“将”、“应该”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“正在进行”或这些术语或其他类似术语的否定词来识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些词语。

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents Akoya files with the Securities and Exchange Commission from time to time.

这些声明涉及风险、不确定性和其他因素，这些因素可能导致实际结果、活动水平、绩效或成就与这些前瞻性声明所表达或暗示的信息存在重大差异。这些风险、不确定性和其他因素在“风险因素”、“管理层对财务状况和经营成果的讨论和分析”以及Akoya不时向证券交易委员会提交的文件中进行了描述。

The reader is cautioned that forward-looking statements are based on a combination of facts and factors currently known by Akoya and Akoya’s projections of the future, about which Akoya cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Akoya’s views as of the date hereof.

读者注意到，前瞻性陈述是基于Akoya目前已知的事实和因素以及Akoya对未来的预测的组合，Akoya对此无法确定。因此，前瞻性陈述可能不会被证明是准确的。截至本新闻稿发布之日，本新闻稿中的前瞻性声明代表了Akoya的观点。

Akoya undertakes no obligation to update any forward-looking statements for any reason, except as required by law..

除法律要求外，Akoya无义务以任何理由更新任何前瞻性声明。。

About Argonaut Manufacturing Services

关于Argonaut制造服务

Argonaut Manufacturing Services is an FDA-registered cGMP contract development and manufacturing organization (CDMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill / finish capabilities feature state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines.

Argonaut Manufacturing Services是一家FDA注册的cGMP合同开发和制造组织（CDMO），致力于为生物制药和诊断公司提供定制制造和供应链解决方案。无菌药物填充/完成功能具有最先进的自动化设备，用于高产量填充无菌注射药物，包括生物制剂，肽，小分子和疫苗。

Diagnostic manufacturing capabilities include proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.

诊断制造能力包括专有冻干技术和一系列配套能力。项目得到了包括仓储和全球航运物流在内的全面分析质量控制服务的支持。Argonaut为生命科学、分子诊断和生物制药行业的创新者提供服务，为不同的外包需求提供各种灵活的解决方案。

For more information, visit: .

有关更多信息，请访问：。

www.argonautms.com

www.argonautms.com

.

.

About Akoya Biosciences

关于Akoya Biosciences

As The Spatial Biology Company

作为空间生物公司

®

®

, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy.

，Akoya Biosciences的使命是通过空间表型的力量为生物学和人类健康世界带来背景。该公司提供全面的单细胞成像解决方案，使研究人员能够根据空间背景对细胞进行表型分析，并可视化它们如何组织和相互作用以影响疾病进展和对治疗的反应。

Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler.

Akoya提供了完整的空间表型分析解决方案，以满足研究人员在发现，转化和临床研究中的不同需求：PhenoCode™面板和PhenoCycler。

®

®

, PhenoImager

，现象成像器

®

®

Fusion, and PhenoImager HT Instruments. To learn more about Akoya, visit

Fusion和PhenoImager HT仪器。要了解更多关于Akoya的信息，请访问

www.akoyabio.com

akoyabio.com网站

.

.